CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma.
OBJECTIVE
DLBCL is a heterogeneous disease with 40% of patients presenting as refractory/relapsing disease following R-CHOP treatment. Few recent studies investigating CD30 expression in DLBCL reported various prognostic effects. This study aimed to evaluate CD30 expression and its correlation with MYC rearrangement and to clarify its prognostic significance in DLBCL.


METHODS
In 98 patients with de novoDLBCL, we studied CD30 expression by immunohistochemistry using different cutoff values (>0%, ≥20%, and ≥40% lymphoma cells, respectively) and correlated with the corresponding MYC rearrangement status by FISH.


RESULTS
The clinicopathologic features were very similar between the CD30+ and CD30- groups. The only major difference was that CD30 expression was nearly exclusively seen in cases without MYC rearrangement. CD30 expression was not predictive of overall survival irrespective of therapy regimens, cell of origin, or MYC rearrangement status (P > 0.05). In the 27 patients receiving aggressive regimens, CD30 expression was associated with better OS (P = 0.008) when all patients were included while the survival advantage was lost (P = 0.21) if MYC rearranged cases were excluded.


CONCLUSIONS
CD30 expression was not associated with prognosis in our cohort of de novoDLBCL, including in patients who received aggressive chemotherapy. CD30 expression and MYC rearrangement were mutually exclusive in de novoDLBCL.
Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Xuan J
XJ
Wang
Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Adam C
AC
Seegmiller
Department of Medicine, Division of Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Nishitha M
NM
Reddy
Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.|Now at Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shaoying
S
Li
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D003131:Combined Modality Therapy; D005260:Female; D015870:Gene Expression; D015322:Gene Rearrangement, B-Lymphocyte; D016259:Genes, myc; D006801:Humans; D016130:Immunophenotyping; D017404:In Situ Hybridization, Fluorescence; D017730:Ki-1 Antigen / Q000235:genetics* / Q000378:metabolism; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
D014408:Biomarkers, Tumor; D017730:Ki-1 Antigen
CD30; MYC; diffuse large B-cell lymphoma